Merck KGaA Changes Manager Incentives, But Stays Mum On Job Losses
This article was originally published in The Pink Sheet Daily
Germany's Merck KGaA implements share-based incentive scheme for top management and vows to improve financial transparency, while discussing cost-savings with employees.
You may also be interested in...
Achillion brought in nearly $42 million in its third large fundraising over the past 24 months, but the virology-focused biotech may become an increasingly sought acquisition target as other hepatitis C candidates face hurdles or are shelved entirely.
A mixture of two antibodies that may have a novel synergistic effect against EGFR-expressing tumors has been licensed to Merck KGaA for development worldwide by Denmark's Symphogen, the recipient back in 2011 of one of the largest ever VC-backed financing rounds in Europe.
The German pharma signs a deal with Indiana-based PDS Biotechnology that will use the company’s adjuvant technology to boost its own compounds.